AACC Announces Program for 2010 Annual Meeting
Washington, DC – June 1, 2010 The American Association for Clinical Chemistry (AACC) announces its program for the 2010 Annual Meeting & Clinical Lab Expo to be held July 25 – 29, 2010 at the Anaheim Convention Center, Anaheim, CA. Over 300 individual sessions will be featured over the course of the five days. Highlights include:
Opening Plenary: The Impact of Biomarkers on the Diagnosis of Alzheimer’s Disease
John Trojanowski, MD, PhD, from the University of Pennsylvania School of Medicine, is the winner of the 2010 Wallace H. Coulter Lectureship Award and a leading figure in the development and characterization of biomarkers of neurological disease. He will discuss the role of novel biomarkers for diagnosis of Alzheimer’s disease, a devastating condition that mainly impacts the elderly and is complicated to evaluate.
A Heart to Serve: A Non-Partisan View of Solving the World’s Most Intractable Problems
Doctor and Senator Bill Frist is both a nationally recognized heart and lung transplant surgeon and former United States Senate Majority Leader. Currently Professor of Business and Medicine at Vanderbilt University, he is uniquely qualified to discuss the challenges of improving healthcare in resource-limited countries.
This session has been developed in cooperation with the American Diabetes Association.
Last year, an international expert committee recommended that hemoglobin A1c replace glucose testing for diagnosis of diabetes. This session brings together laboratorians, endocrinologists, and physicians to review the advantages and disadvantages HbA1c as a diagnostic test and the benefits of using A1c as a screening tool.
The Quest for Clean Competition: Are the Cheaters or Testers Ahead in the Game?
Recent revelations from professional baseball players and world-class cyclists are simply the latest signs that performance-enhancing drugs continue to infiltrate the sporting culture. Anthony Butch, PhD, from the Geffen School of Medicine at UCLA, will examine the race between the doping technologies that some athletes use to gain a competitive advantage and the PED detection tools that help guarantee a level playing field. Dr. Butch will be offering his presentation as part of a session that will also look at the operations of a real-life, “CSI-style” forensic lab.
Inflammation, hsCRP, and Cardiovascular Prevention: A Paradigm Shift
Recently, measurement of very low concentrations of C-reactive protein has gained popularity as an inexpensive means for predicting the risk of cardiovascular disease (CVD): an application made possible by the development of high-sensitivity CRP (hsCRP) assays. Join Paul Ridker, MD, lead investigator of the landmark JUPITER trial, as he discusses utilization of hsCRP testing, the impact that this marker might have on the ability to predict future cardiovascular events, and a new prevention paradigm that includes this inflammatory marker will be presented.
The complete Annual Meeting program is available here. AACC invites interested journalists to apply for a complimentary registration by completing and submitting a Press Registration Form.
For more information about the Annual Meeting or AACC, please contact Peter Patterson on either of the above phone numbers or at ppatterson@aacc.org.
AACC is a leading professional society dedicated to improving healthcare through laboratory medicine. Its over 9,000 members are clinical laboratory professionals, physicians, research scientists, and others involved in developing tests and directing laboratory operations. AACC brings this community together with programs that advance knowledge, expertise, and innovation
